<DOC>
	<DOCNO>NCT01274637</DOCNO>
	<brief_summary>The purpose study determine feasible conduct multi-center randomize trial determine whether blood thinner , low-molecular-weight-heparin ( LMWH ) , effective prevent blood clot , thromboembolism ( VTE ) , postpartum woman risk .</brief_summary>
	<brief_title>PROSPER : PostpaRtum PrOphylaxiS PE Randomized Control Trial Pilot</brief_title>
	<detailed_description>The PROPSER pilot randomize , open-label pilot study compare prophylactic low molecular weight heparin ( LMWH ) saline placebo . The PROSPER pilot study assess feasibility conduct full trial measure number subject recruit per center per month . In addition , clinical data collect determine estimate primary outcome event rate ( symptomatic VTE asymptomatic proximal deep vein thrombosis ( DVT ) major bleed event rate full trial LMWH control group . If pilot result indicate substantial change need study design , include pilot data primary secondary outcome analysis full trial ( i.e . `` Vanguard trial '' internal pilot trial ) . Eligible consent woman risk postpartum thrombosis randomize within 36 hour delivery placenta equally allocate 2 trial arm , either treatment group : prophylactic-dose LMWH , subcutaneously daily 10 day ( +/-3 day ) , control group . At 10 day ( +/- 3 day ) , woman study visit ass study outcome , include bilateral leg ultrasound screen VTE D-dimer test . A final telephone follow-up occur 90 day outcome assessment subsequent VTE , bleed adverse event .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Women must high risk thromboembolism one follow reason : 1 . Known low risk thrombophilia ( Known = diagnose prior enrollment low risk thrombophilia include heterozygous factor V Leiden prothrombin gene variant protein C deficiency protein S deficiency . If previously test assumed thrombophilia ) . 2 . Immobilization ( define &gt; 90 % waking hour bed , week point antepartum period ) . OR two follow reason : 1 . Postpartum infection ( fever ( temperature &gt; 38.5oC ) clinical signs/symptoms infection elevate neutrophil count ( high local lab normal ) ) 2 . Postpartum hemorrhage ( Estimated blood loss &gt; 1000 ml delivery postpartum ) 3 . Prepregnancy BMI &gt; 25 kg/m2 4 . Emergency cesarean birth ( emergency = plan prior onset labour ) 5 . Smoking &gt; 5 cigarette per day prior pregnancy 6 . Preeclampsia ( blood pressure ≥ 140mmHG systolic and/or ≥90 mmHg diastolic least one occasion proteinuria ( 1+ urine dipstick 300mg/dl total excretion 300mg/24 hour ) typical endorgan dysfunction . 7 . Infant birth weight ( adjust sex gestational age ) &lt; 3rd percentile ( i.e. , small gestational age ) . 1 . Less 6 hour 36 hour since delivery time randomization 2 . Need anticoagulation judge local investigator , may include limited : 1 . Personal history previous provoke unprovoked VTE ( DVT PE ) 2 . Continuation LMWH start antenatal period VTE prophylaxis 3 . Mechanical heart valve 4 . Known highrisk thrombophilia ( Known = diagnose prior enrolment highrisk thrombophilia include deficiency antithrombin ( least 1 abnormal lab result ) , persistently positive anticardiolipin antibody ( &gt; 30U/ml two measurement minimum six week apart ) , persistently positive Anti B2 glycoprotein antibody ( &gt; 20U/ml two measurement minimum six week apart ) , persistently positive lupus anticoagulant ( positive two measurement minimum six week apart ) , homozygous factor V Leiden ( FVL ) , homozygous prothrombin gene mutation ( PGM ) , compound heterozygosity factor V Leiden ( FVL ) prothrombin gene mutation ( PGM ) , 1 thrombophilia ( combination 2 : FVL , PGM , protein C deficiency , protein S deficiency ) . If previously test assumed thrombophilia ) . 3 . Contraindication heparin therapy , include : 1 . History heparin induce thrombocytopenia ( HIT ) 2 . Platelet count le 80,000 x 106/L postpartum Complete Blood Count ( CBC ) 3 . Hemoglobin ≤ 75 g/L postpartum CBC 4 . Active bleeding site ( resolve prior randomization ) 5 . Excessive postpartum vaginal bleeding ( &gt; 1 pad per hour prior randomization ) . 6 . Documented gastrointestinal ulcer within 6 week prior randomization 7 . History heparin LMWH allergy 8 . Severe postpartum hypertension ( systolic blood pressure ( SBP ) &gt; 200mm/hg and/or diastolic blood pressure ( DBP ) &gt; 120mm/hg ) 9 . Severe hepatic failure ( INR &gt; 1.8 liver disease suspect ) 4 . Have receive one dose heparin LMWH since delivery 5 . &lt; age legal majority local jurisdiction ( age &lt; 18 Canada ) 6 . Prior participation PROSPER 7 . Unable refuse consent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>postpartum</keyword>
	<keyword>low molecular weight heparin</keyword>
	<keyword>venous thromboembolism</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>Dalteparin Sodium</keyword>
</DOC>